This is a renewal application by the University of California, San Francisco (UCSF) to participate in the scientific activities of the Cancer and Leukemia Group B. UCSF joined the group as an affiliate of the University of California, San Diego, in 1990 and became a main member institution in 1992. The Principal Investigator (PI) on that application was Dr. Henderson, who was succeeded as PI by Dr. Venook upon Dr. Henderson's resignation in 1995. Dr. Venook has been active in CALGB since 1989. The UCSF faculty is very well represented in the scientific endeavors of the group. Eight members serve on core committees: Dr. Venook on the Gastrointestinal and Pharmacology and Experimental Therapeutics Committees; Dr. Small as Vice-Chair of Prostate and Chair of its Correlative Sciences subcommittee; Dr. Warren on Surgery, Gastrointestinal and Solid tumor Correlative Sciences; Dr. Henderson on Breast (former chairman); Dr. Linker on Leukemia; Dr. Triphathy on Solid Tumor Correlative Sciences; Dr. Davoren on the clinical Economics Working Group; and Dr. Kaplan as Vice-Chair of the AIDS Malignancy Working Group. Drs. Tripathy and Esserman head the current CALGB efforts to establish a high-risk breast and ovarian cancer registry. Drs. Venook, Small, Linker, Tripathy and Henderson are PIs on eight current studies; Dr. Warren is a co-PI on two studies and his laboratory is coordinating the correlative science components of each. Dr. Venook directed and has submitted for publication CALGB's study of paclitaxel in patients with liver dysfunction and Dr. Roach presented to the group a first-authored paper on racial issues in breast cancer using CALGB data. Drs. Kaplan and Gray have given plenary session scientific presentations at the group meetings. While accrual in the first three years of this past grant fell below predictions, accrual has improved dramatically and UCSF has met its target for the final year of the grant, with 138 patients accrued, 38 of whom are minorities. The enthusiastic participation of four UCSF hospitals (Moffitt-Long, Mt. Zion, San Francisco General and the Veterans Administration), the addition of an affiliate (St. Joseph's Hospital, Eureka, CA) and the continued intellectual involvement of committed clinical investigators will enable UCSF to maintain and improve upon its performance in the coming years.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Guercio, Brendan J; Sato, Kaori; Niedzwiecki, Donna et al. (2015) Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 33:3598-607
Patel, Jai N; Jiang, Chen; Hertz, Daniel L et al. (2015) Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 121:1025-31
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Shiovitz, Stacey; Bertagnolli, Monica M; Renfro, Lindsay A et al. (2014) CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 147:637-45
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43

Showing the most recent 10 out of 90 publications